IL100623A - PROCESS FOR THE PRODUCTION OF RECOMBINANT IgA PROTEASE AND THE IgA PROTEASE PRODUCED THEREBY - Google Patents
PROCESS FOR THE PRODUCTION OF RECOMBINANT IgA PROTEASE AND THE IgA PROTEASE PRODUCED THEREBYInfo
- Publication number
- IL100623A IL100623A IL10062392A IL10062392A IL100623A IL 100623 A IL100623 A IL 100623A IL 10062392 A IL10062392 A IL 10062392A IL 10062392 A IL10062392 A IL 10062392A IL 100623 A IL100623 A IL 100623A
- Authority
- IL
- Israel
- Prior art keywords
- iga protease
- modified
- gene
- iga
- recombinant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000008569 process Effects 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 title description 19
- 239000004365 Protease Substances 0.000 title description 17
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title description 16
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims abstract description 99
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 230000004913 activation Effects 0.000 claims abstract description 10
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 9
- 238000004153 renaturation Methods 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 16
- 108020004511 Recombinant DNA Proteins 0.000 claims description 16
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 108020004705 Codon Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 238000005063 solubilization Methods 0.000 claims description 3
- 230000007928 solubilization Effects 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 239000000872 buffer Substances 0.000 description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 108010077112 prolyl-proline Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710173814 UvrABC system protein A Proteins 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Process for the production of recombinant IgA protease, wherein (1) an IgA protease gene is modified in such a way that the DNA region of the IgA protease gene coding for the C-terminal helper sequence is no longer functionally active, (2) a host cell is transformed with the IgA protease gene modified according to step (1) or with a vector containing this modified gene, (3) the modified IgA protease gene is expressed in the transformed host cell, (4) the IgA protease which forms as inactive inclusion bodies is isolated from the host cell and (5) the IgA protease is converted into active protein by in vitro activation.
Description
Ref: 7076/99 100623/4 πτκΰ"Π9 IgA -m rrcirnmpn mauns IgA "w1? τ?ηη A PROCESS FOR THE PRODUCTION OF RECOMBINANT IgA PROTEASE AND THE IgA PROTEASE PRODUCED THEREBY D e s c r i p t i o n The present invention concerns a process for the production of recombi ant IgA protease and its expression in a transformed host ceil.
Various pathogenic bacterial species (e.g. of the genus Neisseria, such as for example Neisseria gonorrhoeae and Neisseria meningitidis or the genus Haemophilus such as for example Haemophilus influenzae) which grow on human mucous membranes secrete proteases which are specific for human Ig Al and which are denoted IgA proteases. The immunoglobulin Ig Al is an important component of the secretory immune response that is intended to protect against infections by such pathogenic organisms (review: Kornfeld and Plaut, Ref . Infec . Dis . 3 (1981), 521-534). These proteolytic enzymes, which are denoted IgA proteases, for example cleave the following recognition sequences as described for example by Pohlner et al., (Nature 325 (1987), 458-462): 1. ?ro-Aia-Pro - Ser-Pro 2. Pro-Pro - Ser-Pro 3. . Pro-Pro - Ala-Pro 4. Pro-Pro - Thr-Pro In this case in each case denotes the cleavage site of the IgA protease.
The IgA proteases mentioned above are secretory proteins which have an N-terir.inal signal sequence for the transport into the periplas a and a C-terminal helper protein sequence which subsequently allows secretion from the periplasma into the medium.
The cloning and expression of an IgA protease from Neisseria in E- coli is described for example in PNAS USA 79 (1932) 7381-7385 and EMBO J. 3 (1984) 1595-1601.
Grundy et ai., J. of Bact . 159 ( 10 ) : 4 42-445C ( 1987 ) describes the preparation of IgAl protease in E. Coli. An IgAl. protease is prepared which is not secreted in the medium, but which is localized in the peripiasmic space in the active form.
Kcronakis et al., EMBOJ 8 (2 ) : 595-605 { 1989) describes C-terminal sequences of hemolysin, which make possible the transport of che protein across the membrane.
Claassen et al., J. 3iol. Che.m 266 ( 17 ) : 11380-11387 ( 1991) describes the purification of deletion mutants of the UvrA protein from inclusion bodies after espression in E. Coli. Meyer (EP-A-0 254 090) describes a process for the production of proteins in E. coli using a vector containing the coding foreign gene within the sequence of the IgA protease precursor gene.
A disadvantage of the isolation of IgA protease according to the known methods is, however, the low productivity and vitality of the E. coli cells which have been transformed with an IgA protease gene which only results in a very low volume yield of IgA protease.
Since IgA protease is very important as .a proteolytic enzyme for the cleavage of fusion proteins produced by genetic engineering (cf. WO91/11520) there is a great need for a method of isolating IgA protease which overcomes at least some of the drawbacks of the state of the art. 100623/2 - 2a - The object according to the present invention is to provide a process for the production of recombinant IgA protease which is characterized in that (1) an IgA protease gene is modified in such a way that the DNA region of the IgA protease gene coding for the C-terminal helper sequence is no longer functionally active, (2) a host cell is transformed with the IgA protease gene modified according to step (1) or with a vector containing this modified gene, (3) the modified IgA protease gene is expressed in the transformed host cell, (4) the IgA protease which forms as inactive inclusion bodies is isolated from the host cell and - 3 - (5) the IgA protease is converted into active protein by in vitro activation.
It was surprisingly found 'that an IgA protease which no longer has a functionally active helper sequence (and thus can no longer be secreted from the host cell into the medium) is formed as inactive inclusion bodies within the host cell and that after activation of these inactive inclusion bodies very high volume yields of IgA protease are achieved. These inactive inclusion bodies can be isolated according to the usual methods from the cells and subsequently converted into the active form by means of in vitro activation.
It is essential for the process according to the present invention that the DNA region coding for the C-terminal helper sequence of the IgA protease is no longer functionally active. This can for example be achieved by partial or complete deletion of the DNA region coding for the helper, sequence. The deletion of DNA fragments can be carried out in a manner familiar to one skilled in the art, as for example by in vitro mutagenesis on double-stranded or single-stranded DNA or by cleavage with suitable restriction enzymes and removal of restriction fragments from the region of the helper sequence. A further possibility for such a modification of the IgA protease gene is to carry out an in vitro mutagenesis in the DNA region coding for the helper sequence by means of which one or several translation stop codons are introduced into this region which then prevent a complete translation of the helper sequence when the IgA protease gene is expressed.
It is preferred in the process according to the present invention that the IgA protease gene is modified in such - 4 - a way that the helper sequence of the IgA protease coded by this modified gene is completely deleted. This can for example be achieved by introducing one or several translation stop codons into the IgA protease gene directly at the beginning of the C-terminal helper sequence. A further possibility for the deletion of the helper sequence is a PCR reaction on IgA protease cDNA using suitable primers as described in example 1.
In the process according to the present invention it is also preferred that the IgA protease gene is in addition modified in such a way that the DNA region coding for the N-terminal signal sequence of the IgA protease is no longer functionally active. In this way the transport of the IgA protease into the periplasma is also blocked so that the inactive inclusion bodies are formed in the cytosol of the transformed host cell.
It is preferred that the inactivation of the signal sequence is carried out by completely deleting, the corresponding DNA region according to the usual techniques. Subsequently DNA sequences from the DNA regions coding for the mature protein which may have been lost can be filled in again by introducing a synthetic oligonucleotide by genetic engineering. The signal sequence can, however, also be deleted by a PCR reaction using suitable primers as described in example 1.
A prokaryotic cell, especially an E. coli cell, is preferably used as the host cell for the process according to the present invention. In addition it is preferred that the host cell is transformed with a DNA sequence coding for an IgA protease which is under the control of an inducible promoter. Examples of suitable - 5 - inducible promoters are for example the tac, lac or trp promoter or other similar promoters which are known to one skilled in the area of molecular biology.
The IgA protease produced- in the process according to the present invention is formed in the host cell as inclusion bodies. The isolation of inclusion bodies and their conversion into active protein by in vitro activation can be carried out in any manner known to one skilled in the art. Examples of such methods are described for example in EP-A 0 361 475, DE-A 36 11 817, DE-A 35 37 708, WO 87/02673; Jaenicke, R. & Rudolph, R. (1989) Protein structure - a practical approach, Ed.: Creighton T.E. Oxford University Press, 191; Rudolph, R. (1990) Modern methods in protein and nucleic acid analysis, Ed.: Tschesche, published by H. Walter deGruyter, 149-171; Jaenicke, R. (1987) Prog. Biophys. Molec. Biol. 49, 117.
The in vitro activation, of the IgA protease preferably includes a solubilization step and a renaturation step. The renaturation step in this process can be carried out by feeding the denatured protein continuously or discontinuously into the renaturation buffer. In this process it is preferred that the renaturation step is carried out in the form of a discontinuous pulse renaturation.
It is particularly preferred that the renaturation step for the activation of the IgA protease is carried out in the presence of 0.2 to 1 mol/1 arginine and most preferably of 0.4 to 0.8 mol/1 arginine. In addition it is preferred that the reactivation is carried out at a pH of 5 to 9, particularly preferably at a pH of 6 to 8. - 6 - When the IgA protease is renatured from inactive inclusion bodies active soluble protein is formed in a yield which ranges from about 10 % to over 30 %, depending on the starting material and renaturation method. Although the renaturation yield is not quantitative, nevertheless a substantially higher yield of active IgA protease is obtained with the process according to the present invention compared to conventional methods.
The present invention also concerns an IgA protease which has been produced by a process according to the present invention i.e. by activation from inclusion bodies.
In addition the invention concerns a recombinant DNA which codes for an IgA protease and is modified in such a way that on expression . of the recombinant DNA an, IgA protease results whose C-terminal helper .sequence is no. longer functionally . active and is preferably even completely deleted. The recombinant DNA according to the present invention is preferably additionally modified in such a way that on expression of the recombinant DNA an IgA protease is formed whose N-terminal signal sequence is no longer functionally active and especially preferably is completely deleted. Genetic engineering methods for the modification or deletion of DNA regions which lead to the desired results have already been mentioned or are so familiar to one skilled in the area of molecular biology that they do not have to be explicitly elucidated.
The present invention also concerns a recombinant vector which contains at least one copy of a recombinant DNA according to the present invention. The recombinant DNA - 7 - according to the present invention in this vector is preferably under the control of an inducible promoter. The vector according to the present invention can be present outside the chromosome of the host cell (e.g. a plasmid) or integrated in the genome of the host cell (e.g. bacteriophage . in an E. coli cell) . The vector is preferably a plasmid.
The invention in addition concerns a cell which is transformed with a recombinant DNA according to the present invention or with a recombinant vector according to the present invention. This cell is preferably a prokaryotic cell and particularly preferably an E. coli cell.
The invention is further elucidated in the following by the present examples in conjunction with the sequence protocols .
SEQ. ID. NO. 1 shows the primer A used example 1 SEQ. ID. NO. 2 shows the primer B SEQ. ID. NO. 3 shows the primer C SEQ. ID. NO. 4 shows the primer D The plasmid pMAC 1 was deposited at the German Collection for Microorganisms (DSM) , GriesebachstraBe 8, D-3400 Gottingen and assigned the number DSM 6261. - 8 - E x a m p l e 1 Preparation of plasmid constructs for the expression of IgA protease in the form of inclusion bodies In order to express IgA protease as inclusion bodies, the region coding for the protein without signal sequence and helper sequence is cloned downstream of a strong promoter as described in the following (amino acid position + 1 to position 959, Pohlner J., Halter R. , Beyreuther K., Meyer T.F., Nature 325, (1987), 458-462) .
For this chromosomal DNA is isolated from N. gonorrhoeae (e.g. MS 11) and used to carrying out a polymerase chain reaction (PCR, method cf. EP-A 0 200 362, EP-A 0 201 184) . The following primers are used for the PCR.
Primer A (SEP. ID. NO. 1) : 5 ' GAAGAATTCGGAGGAAAAATTAATGGCACTGGTACGTGATGATGTCGATTATCAAA 3 ' Primer B (SEP. ID. NP. 2): 5' TTTTTGTAATAAAGATCTTTGCCTTG 3' The first 5 codons of the IgA protease were optimized for an efficient expression in E. coli without changing the amino acid sequence and used for primer A, which includes the ATG start codon as well as an ECo RI recognition sequence (GAATTC) . - 9 - Primer B contains sequences adjacent to the Bgl II recognition sequence of the IgA protease (ca. amino acid positions 553-561) . The PCR fragment (A/B = ca. 1650 bp, 5' terminal region of the IgA protease gene) obtained in this way is purified and recleaved with the enzymes ECo RI/Bgl..II.
In order to prepare the 3 ' region of the IgA protease gene a second PCR reaction is carried out with the following primers: Primer C (SEP. ID. NO. 3) : 5 ' CAAGGCAAAGATCTTTATTACAAAAA 3 ' Primer D (SEP. ID. NO. 4): 5 ' TTCAGCTGGTCGACTTATCACGGGGCCGGCTTGACTGGGCGGCC 3 ' ' Primer C corresponds to the coding region of primer B (Bgl II cleavage site) and primer D contains sequences of amino acid positions 952-959 with an adjacent stop codon and a Sal I recognition sequence. The PCR fragment (C/D = 1200 bp) obtained in this way is isolated and recleaved with the enzymes Bgl II/Sal I.
Subsequently a three fragment ligation is carried out: with the fragments A/B, the fragment C/D and the vector pK 223-3 (DSM 3694P) which was previously digested with the enzymes Eco RI and Sal I and purified. The vector obtained in this way is denoted IgA-Prot III and is transformed in E. coli 12. - 10 - Example 2 (comparative example) Isolation of soluble IgA protease according to the conventional method. a) Isolation from 1 1 shaking culture E. coli K12 cells transformed with the plasmid p ACl (8878 bp) were used as the starting material. The complete coding region for IgA protease is located on this plasmid and is under the control of the lambda promoter. The plasmid carries an ampicillin resistance.
The cells were cultured in LB medium overnight at 28 °C and subsequently diluted 1:100 with LB medium. The culture was then incubated for a further 4 hours at 37 °C. The cells were separated by a centrifugation step. The culture supernatant was sterile-filtered over a cellulose-acetate filter, dialysed against 20 mmol/1 Tris/HCl, pH 7.5, 10 mmol/1 EDTA, 10 % glycerol (buffer A) and concentrated to 1/10 its volume with the aid of a SALVIA capillary dialyser E-15U.
A negative elution on DEAE-Sephadex A-50 in 20 mmol/1 Tris/HCl, pH 7.5, 10 mmol/1 EDTA and 10 % glycerol was carried out as the first purification step. The column was loaded with 0.5 mg protein per 1 ml gel matrix. In this separation the IgA protease is in the eluant and most of the E. coli proteins are bound to the carrier.
Washing the column matrix again with buffer A plus 1 mol/1 NaCl showed that less than 10 % of the IgA protease binds' to the column material. - 11 - Finally it is purified on a cation exchanger (FractogelR-EMD-S03" -650M) . The protein binds in 20 mmol/1 Tris/HCl, 10 mmol/1 EDTA, 10 % glycerol pH 7.0. Then the buffer can be changed to pH 8.0. The elution is carried out with a linearly increasing NaCl gradient whereby the IgA protease is eluted with a buffer of pH 8.0 at a salt concentration of 0.1 mol/l NaCl and with a buffer of pH 7.0 at 0.2 mol/l NaCl.
Result: Concentrate before DEAE-Sephadex 3.5 mg protease (70 % pure) Eluate after DEAE-Sephadex 2.4 mg protease (90 % pure) Eluate after FractogelR-EMD-S03" -650M 1 mg protease (> 95 % purity) b) Isolation of IgA protease from a 10 1 fermenter The starting material and purification were carried out analogous to example 2a) .
Result: Concentrate before DEAE-Sephadex: 50 mg IgA protease (50 % purity) Eluate after DEAE-Sephadex: 30 mg IgA protease (60 % purity) Eluate after FractogelR-EMD-S03' -650M: 12 mg IgA protease (> 95 % purity) - 12 - Example 3 Isolation of IgA protease from inclusion bodies (process according to the present invention) The starting material was the construct IgA-Prot III (example 1) in E. coli cells (DSM 3689) which additionally contain a lacl^ plasmid for the expression of the lac repressor. 500 ml LB medium containing 50 ^g/ml kanamycin and 50 μg/ml ampicillin was prepared for the 1 1 fermentation culture. This medium was inoculated with 7.5 ml of an overnight culture which resulted in an OD550 of ca' °·1· Tnen a 3 to 4 hour incubation at 37 °C was carried out while shaking (150 rpm) . The cells were induced with 5 mmol/1 IPTG at an OD55Q of ca. 0.8. The cells were harvested after a 4 hour incubation at 37°C while shaking (150 rpm) .
IB preparation: The cells are harvested by centrifugation, taken up in 10 ml Tris-magnesium buffer (10 mmol/1 Tris, pH 8.0, 1 mmol/1 gCl2) and lysed with lysozyme (0.3 mg/ml) .
They are incubated for 15 minutes at 37 °C and subjected to one passage of a French press (1200 psi) .
Subsequently a DNAse digestion (1 mg DNAse I) is carried out for 30 minutes at 37 °C. - 13 - 20 ml 0.5 mol/1 NaCl, 20 mmol/1 EDTA, pH 8.0 and 3 ml 20 % Triton X 100 is added and incubated for 10 minutes at room temperature.
The suspension is centrifuged for 10 minutes at 15000 rpm and 4°C. The pellet is taken up in 30 ml 50 mmol/1 T is, pH 8.0, 50 mmol/1 EDTA and 0.5 % Triton X 100 and treated with ultrasound. It is centrifuged again, resuspended and treated with ultrasound. This procedure is repeated for a further two times. Subsequently it is centrifuged and the pellets obtained in this way are used as IBs in example 3.
Table 1 shows the results for the fermentation in a 1 1 shaking culture and in a 10 1 fermenter.
Table 1 Fermentation E. coli Total protein IgA protease strain from IB material (%) (9) (g) 1 1 HB 101 0.125 50-70 0.06-0.09 10 1 K12 C600 20.8 30-50 6.2-10.4 It can be seen from Table 1 that 60-90 mg protease is obtained as inclusion body (IB) material from the 1 1 shaking culture. At a renaturation yield of ca. 10 % this would yield 6 to 9 mg active IgA protease (compared to 3.5 mg by the conventional method). 6.2 to 10.4 g protease is obtained as IB material from the 10 1 fermenter. This would yield 620 to 1040 mg IgA - 14 - protease if 10 % is renatured (compared to 50 mg protease by the conventional method) .
It can be clearly seen from these results that the process according to the present invention results. in an increase in the yield of at least 2 to 3-fold (1 1 culture) or 20 to 30-fold (10 1 fermenter) .
Example 4 Renaturation of the IgA protease from inclusion bodies (1 1 fermentation) The inclusion bodies were first solubilized, then dialyzed and then renatured in the respective buffers.
Solublization of the IB material: 6 mol/1 guanidine/HCl, pH 8.5 0.1 mol/1 Tris 1 mmol/1 EDTA 0.1 mol/1 dithioerythreitol (DTE) Incubation: 2 h at room temperature Vol: 10 ml, protein concentration: 10 mg/ml Dialysis of the solubilisate: 6 mol/1 guanidine/HCl, pH 3 1 mmol/1 EDTA Duration: 12 h at room temperature against 10 1 buffer - 15 - Renaturation buffer: 1) 100 mmol/1 Tris, 1 mmol/1 EDTA, 1 mmol/1 DTE, pH 8.5 2) 100 mmol/1 Tris, 1 mmol/1 EDTA, 1 mmol/1 DTE, pH 7.5 3) 20 mmol/1 Tris, 1 mmol/1 EDTA, 1 mmol/1 DTE, pH 8.0 4) 0.6 mol/1 Arg/HCl, 1 mmol/1 EDTA, 1 mmol/1 DTE, pH 8.0 5) 0.6 mol/1 Arg/HCl, 1 mmol/1 EDTA, 5 mmol/1 reduced glutathione (GSH)/0.5 mmol/1 oxidized glutathione (GSSG) , pH 8 Pulse renaturation: The denatured protein is added in 5 portions to the renaturation buffer; the time interval between the individual additions was 30 minutes and the protein concentration in the preparation increased by 20 μg/ml per pulse. The final protein concentration was eventually 100 g/ml.
In order to determine the activity of the renatured IgA protease a dialysis is carried out in cleavage buffer (50 mmol/1 Tris/HCl pH 8, 1 mmol/1 CaCl2) . Human IgA was used as the cleavage substrate. Table 2 shows the results of the cleavage experiments (incubation: 6 h at 37 °C) on the renaturates obtained by using the above renaturation buffers (1-5) . - 16 - Table 2 Cleavage of human IgA with IgA protease isolated according to the present example (incubation: 6 h at 37 °C) . The isolate obtained after the dialysis contains about 50 % IgA protease.
Renaturate Ratio Cleavage protease/substrate (%) 1 1:20 10 2 1:20 30 3 1:20 10 4/5 1:100 100 1:500 50 1: 1000 30 1:2000 10 1:5000 5 soluble protease (100 % pure) It can be seen in Table 2 that IgA protease can be renatured in all buffers. The yields in an arginine (Arg) buffer are, however, 10 to 100-fold higher than without arginine. As a comparison the substrate was cleaved by 100 % with soluble purified IgA protease (according to example 1) at a protease: substrate ratio of 1:500. From this a renaturation yield of ca. 50 % can be determined for buffer 4) and 5) . - 17 - Example 5 Dependence of the optimization of the renaturation of IgA protease from inclusion bodies on the pH and arginine concentration Solubilization and dialysis are analogous to example 4.
Pulse renaturation: protein addition was carried out as described in example 4. 1) Determination of the renaturation yield while varying the pH value. 0.6 mol/1 Arg/HCl 1 mmol/1 EDTA pH 4, 6, 8 2) Renaturation while varying the arginine concentration 1 mmol/1 EDTA, pH 3 1 mmol/1 DTE Arg/HCl: 0.2; 0.4; 0.6 and 0.8 mol/1 Subsequently a dialysis was carried out at room temperature against a 100-fold volume of the cleavage buffer (50 mmol/1 Tris/HCl, pH 8, 1 mmol/1 CaCl2) . - 18 - Table 3 Cleavage of human IgA with the aid of the IgA protease isolated according to the present example. The dialysate contains about 50 to 70 % IgA protease. In the cleavage preparation 50 μg substrate was incubated with 1 μ<¾ renatured IgA protease for 6 h at 37°C. pH % Cleavage Arginine (mol/1) % Cleavage 4 10 0.2 85 6 95 0.4 90 8 100 0.6 95 0.8 95 The optimal reactivation of the IgA protease is at a pH of 6 to 8 and at an arginine concentration of 0.6 to 0.8 mol/1.
Claims (22)
1. Process for the production of recombinant IgA protease, w h e r e i n (1) an IgA protease gene is modified in such a way that the DNA region of the IgA protease gene coding for the C-terminal helper sequence is no longer functionally active, (2) a host cell is transformed with the IgA protease gene modified according to step (1) or with a vector containing this modified gene, (3) the modified IgA protease gene is expressed in the transformed host cell, (4) the IgA protease which forms as inactive inclusion bodies is isolated from the host cell and (5) the IgA protease is converted into active protein by in vitro activation.
2. Process as claimed in claim 1, w h e r e i n the IgA protease gene is modified in such a way that the C-terminal helper sequence of the IgA protease resulting from the expression of the modified gene is completely deleted.
3. Process as claimed in claim 1 or 2, w h e r e i n one or several translation stop codons are introduced into the DNA region coding for the helper sequence or the DNA region coding for the helper sequence is partially or completely deleted. -_,20 -
4. Process as claimed in one of the claims 1 to 3, w h e r e i n the IgA protease gene is additionally modified in such a way that the DNA region of the IgA protease gene coding for the N-terminal signal sequence is no longer functionally active.
5. Process as claimed in claim 4, w h e r e i n the IgA protease gene is modified in such a way that the N-terminal signal sequence of the IgA protease resulting from the expression of the modified gene is completely deleted.
6. Process as claimed in one of the previous claims, w h e r e i n a prokaryotic cell is used as the host cell.
7. Process as claimed in claim 6, w h e r e i n an E. coli cell is used as the host cell.
8. Process as claimed in one of the previous claims, w h e r e i n the host cell is transformed with an IgA protease gene which is under the control of an inducible promoter.
9. Process as claimed in one of the previous claims, w h e r e i n the in vitro activation of the IgA protease includes a solubilization step and a renaturation step.
10. Process as claimed in claim 9, w h e r e i n the renaturation step is carried out as a pulse renaturation. -21-
11. Process as claimed in claim 9 or 10, wherein the renaturation step is carried out in the presence of 0.2 to 1 mol/1 arginine.
12. Process as claimed in claim 11, wherein a concentration of 0.4 to 0.8 mol/1 arginine is used.
13. Process as claimed in one of the claims 9 to 12, wherein the renaturation step is carried out at a pH of about 6 to 8.
14. Recombinant IgA protease produced by a process as claimed in one of the claims 1 to 13.
15. Recombinant DNA, which codes for an IgA protease according to claim 14, said DNA being modified in such a way that when the recombinant DNA is expressed an IgA protease is formed whose C-terminal helper sequence and whose N-terminal signal sequence within the IgA protease encoded thereby are no longer functionally active.
16. Recombinant DNA as claimed in claim 15, wherein on expression of the recombinant DNA an IgA protease is formed whose helper sequence is completely deleted.
17. Recombinant DNA as claimed in claim 16, wherein on expression of the recombinant DNA an IgA protease is formed whose signal sequence is completely deleted.
18. Recombinant vector, wherein it contains at least one copy of a recombinant DNA as claimed in one of the claims 15 to 17.
19. Recombinant vector, wherein the recombinant DNA is under the control of an inducible promoter.
20. Cell, wherein it is transformed with a recombinant DNA as claimed in one of the claims 15 to 17 or with a recombinant vector as claimed in claim 18 or 19.
21. Cell as claimed in claim 20, wherein it is a prokaryotic cell. 100623/3 -22-
22. Cell as claimed in claim 21, wherein it is an E. coli cell. Use of the recombinant IgA protease as claimed in claim 14 for the cleavage of fusion proteins produced by genetic engineering, substantially as described in the specification. LUZZATTO & LUZZATTO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4100704 | 1991-01-11 | ||
| DE4140699A DE4140699A1 (en) | 1991-01-11 | 1991-12-10 | RECOMBINANT IGA PROTEASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL100623A0 IL100623A0 (en) | 1992-09-06 |
| IL100623A true IL100623A (en) | 2002-07-25 |
Family
ID=25900194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10062392A IL100623A (en) | 1991-01-11 | 1992-01-09 | PROCESS FOR THE PRODUCTION OF RECOMBINANT IgA PROTEASE AND THE IgA PROTEASE PRODUCED THEREBY |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0495398B1 (en) |
| JP (1) | JP2509410B2 (en) |
| AT (1) | ATE174627T1 (en) |
| AU (1) | AU636261B2 (en) |
| CA (1) | CA2058872C (en) |
| DE (2) | DE4140699A1 (en) |
| DK (1) | DK0495398T3 (en) |
| ES (1) | ES2127732T3 (en) |
| FI (1) | FI103132B (en) |
| HU (1) | HU215188B (en) |
| IE (1) | IE914559A1 (en) |
| IL (1) | IL100623A (en) |
| NZ (1) | NZ241280A (en) |
| TW (1) | TW197470B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009395A2 (en) * | 1994-09-21 | 1996-03-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases |
| GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
| AU9341398A (en) * | 1997-08-22 | 1999-03-16 | Boehringer Mannheim Gmbh | Protease precursors that can be autocatalytically activated and their use |
| CA2301698A1 (en) * | 1997-08-22 | 1999-03-04 | Roche Diagnostics Gmbh | Zymogenic protease precursors that can be autocatalytically activated and their use |
| AU7053500A (en) * | 1999-09-15 | 2001-04-17 | Eli Lilly And Company | Chymotrypsin-free trypsin |
| WO2010118337A2 (en) * | 2009-04-10 | 2010-10-14 | Biomarin Pharmaceutical Inc. | Methods of enhancing yield of active iga protease |
| AU2024292159A1 (en) | 2023-07-19 | 2026-01-22 | F. Hoffmann-La Roche Ag | Dsfv as an igg fragment format and methods of production and labelling thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3622221A1 (en) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | METHOD FOR THE GENE-TECHNOLOGICAL EXTRACTION OF PROTEINS USING GRAM-NEGATIVE HOST CELLS |
| DE3832898A1 (en) * | 1988-09-28 | 1990-04-12 | Boehringer Mannheim Gmbh | PRAEPARATE OF EXPRESSED PLASMINOGEN ACTIVATOR IN PROKARYONS |
| DK130889A (en) * | 1989-03-17 | 1990-09-18 | Mogens Kilian | IMMUNOGLOBULIN A1 PROTEASES (IGA1 PROTASES), PROCEDURES FOR GENTECHNOLOGICAL PREPARATION OF SUCH ENZYMES, AND VACCINE-CONTAINING ENZYMES AND SYMBOLS OF PROMISTS OF BACKGROUND IMMUNISTRY AND BIT |
-
1991
- 1991-12-10 DE DE4140699A patent/DE4140699A1/en not_active Withdrawn
- 1991-12-23 IE IE455991A patent/IE914559A1/en not_active IP Right Cessation
- 1991-12-31 TW TW080110300A patent/TW197470B/zh active
- 1991-12-31 AU AU90116/91A patent/AU636261B2/en not_active Ceased
-
1992
- 1992-01-07 CA CA002058872A patent/CA2058872C/en not_active Expired - Lifetime
- 1992-01-09 ES ES92100288T patent/ES2127732T3/en not_active Expired - Lifetime
- 1992-01-09 DK DK92100288T patent/DK0495398T3/en active
- 1992-01-09 IL IL10062392A patent/IL100623A/en not_active IP Right Cessation
- 1992-01-09 AT AT92100288T patent/ATE174627T1/en not_active IP Right Cessation
- 1992-01-09 DE DE59209590T patent/DE59209590D1/en not_active Expired - Lifetime
- 1992-01-09 EP EP92100288A patent/EP0495398B1/en not_active Expired - Lifetime
- 1992-01-10 HU HU9200092A patent/HU215188B/en not_active IP Right Cessation
- 1992-01-10 NZ NZ241280A patent/NZ241280A/en not_active IP Right Cessation
- 1992-01-10 JP JP4002851A patent/JP2509410B2/en not_active Expired - Lifetime
- 1992-01-10 FI FI920117A patent/FI103132B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| HUT63654A (en) | 1993-09-28 |
| IE914559A1 (en) | 1992-07-15 |
| DE4140699A1 (en) | 1992-07-16 |
| CA2058872C (en) | 1999-12-21 |
| DE59209590D1 (en) | 1999-01-28 |
| JP2509410B2 (en) | 1996-06-19 |
| EP0495398A1 (en) | 1992-07-22 |
| FI920117A0 (en) | 1992-01-10 |
| NZ241280A (en) | 1993-10-26 |
| CA2058872A1 (en) | 1992-07-12 |
| ES2127732T3 (en) | 1999-05-01 |
| AU9011691A (en) | 1992-09-10 |
| TW197470B (en) | 1993-01-01 |
| HU215188B (en) | 1998-10-28 |
| ATE174627T1 (en) | 1999-01-15 |
| FI103132B1 (en) | 1999-04-30 |
| IL100623A0 (en) | 1992-09-06 |
| EP0495398B1 (en) | 1998-12-16 |
| FI103132B (en) | 1999-04-30 |
| DK0495398T3 (en) | 1999-08-23 |
| AU636261B2 (en) | 1993-04-22 |
| HU9200092D0 (en) | 1992-03-30 |
| FI920117L (en) | 1992-07-12 |
| JPH05168478A (en) | 1993-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5427927A (en) | Process for the enzymatic cleavage of recombinant proteins using IgA proteases | |
| EP0230869B1 (en) | Construction of an igg binding protein to facilitate downstream processing using protein engineering | |
| WO1984003103A1 (en) | Method of producing and selectively isolating proteins and polypeptides, recombinant and expression vector therefor and fusion protein able to bind to the constant region of immunoglobulins | |
| JP2004520049A (en) | Method for producing recombinant trypsin | |
| CA2058872C (en) | Recombinant iga protease | |
| CN115867661A (en) | Production of soluble recombinant proteins | |
| US5965424A (en) | Methods for making neisseria or hemophilus IgA protease and DNA encoding the proteases | |
| US5082775A (en) | Efficient process for isolating insoluble heterologous protein using non-ionic detergents | |
| US6955910B2 (en) | Method for large scale production of recombinant DNA-derived TPA or K2S molecules | |
| JP2003512050A (en) | Expression of recombinant mature lysostaphin | |
| KR102643064B1 (en) | Human enterokinase fusion protein with improved expression level and solubility and a preparing method thereof | |
| EP0312346B1 (en) | E. coli sequence specific acid protease | |
| JP2711148B2 (en) | Gene expression method from Streptomyces | |
| EP1981978A2 (en) | Affinity polypeptide for purification of recombinant proteins | |
| KR100206731B1 (en) | Process for purifying serine protease using recombinant inhibitor from erythrina caffra | |
| JP4651203B2 (en) | Novel glutaminase and method for producing the same | |
| CA2185436C (en) | Use of a recombinant inhibitor from erythrina caffra for purifying serine proteases | |
| JP2003038195A (en) | Method of obtaining useful protein from fusion protein | |
| CN114480353A (en) | Method for preparing recombinant human akkerplasmin | |
| JPH03219892A (en) | Method for preparing protein | |
| JPH0588110B2 (en) | ||
| JPH02186988A (en) | Production of antiviral protein | |
| MXPA01009979A (en) | Production of pancreatic procarboxy-peptidase b, isoforms and muteins thereof, and their use | |
| JPS60145090A (en) | DΝA | |
| JP2000083694A (en) | Purification of polypeptide and kit reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |